| __timestamp | ACADIA Pharmaceuticals Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 32748000 | 17986000 |
| Thursday, January 1, 2015 | 90804000 | 32480000 |
| Friday, January 1, 2016 | 186456000 | 68081000 |
| Sunday, January 1, 2017 | 255062000 | 169906000 |
| Monday, January 1, 2018 | 265758000 | 248932000 |
| Tuesday, January 1, 2019 | 325638000 | 354100000 |
| Wednesday, January 1, 2020 | 388661000 | 433300000 |
| Friday, January 1, 2021 | 396028000 | 583300000 |
| Saturday, January 1, 2022 | 369090000 | 752700000 |
| Sunday, January 1, 2023 | 402466000 | 887600000 |
| Monday, January 1, 2024 | 1007200000 |
Unleashing insights
In the competitive landscape of biotechnology, managing operational costs is crucial for sustained growth. Over the past decade, from 2014 to 2023, Neurocrine Biosciences, Inc. and ACADIA Pharmaceuticals Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. Neurocrine Biosciences has seen a staggering increase of nearly 4900% in SG&A expenses, peaking in 2023. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, ACADIA Pharmaceuticals experienced a more moderate rise of approximately 1100%, indicating a steady but cautious approach to scaling operations. By 2023, Neurocrine's SG&A expenses were more than double those of ACADIA, highlighting their divergent strategies. This data not only underscores the dynamic nature of the biotech industry but also offers insights into how these companies prioritize their resources to drive innovation and market presence.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs ACADIA Pharmaceuticals Inc. Trends and Insights
ADMA Biologics, Inc. or ACADIA Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? ACADIA Pharmaceuticals Inc. or MannKind Corporation
Cost Management Insights: SG&A Expenses for ACADIA Pharmaceuticals Inc. and Geron Corporation
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
ACADIA Pharmaceuticals Inc. vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends